They may be suitable for people who want a needle-free alternative to GLP-1 injections, subject to BMI, medical history, current medicines and prescriber approval
Intrapatient changes in CT-based body composition after initiation of semaglutide (glucagon-like peptide-1 receptor agonist) therapy
This ensures that the benefits outweigh the risks based on the individuals medical history, current health status, and weight management goals
over-the-counter omega-3 supplements are not recommended by NICE for cardiovascular disease prevention The key distinction is that GLP-1 receptor agonists are not prescribed primarily for lipid modification
Monitor your progress
Previously, BMO had been anticipating weight loss of about 20%-23% for retatrutide, which targets GIP, GLP-1 and glucagon, along with 50% pain reduction